# rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)

> **NCT04302805** · PHASE3 · COMPLETED · sponsor: **Institute for Clinical and Experimental Medicine** · enrollment: 17 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Privigen
- **DRUG:** Thymoglobulin
- **OTHER:** Plasma Exchange

## Key facts

- **NCT ID:** NCT04302805
- **Lead sponsor:** Institute for Clinical and Experimental Medicine
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-27
- **Primary completion:** 2024-04-15
- **Final completion:** 2024-06-15
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04302805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04302805, "rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04302805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*